Replimune stock.

6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Jul 9, 2023 · Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy. Replimune ( REPL) shares fell early this month after the company disclosed in its latest 10Q filing that the FDA raised certain issues related to CERPASS, including those on study endpoints, for ...Replimune Group Inc. Watch list Set a price target alert After Hours Last Updated: Nov 29, 2023 4:02 p.m. EST Delayed quote $ 11.32 0.00 0.00% After Hours Volume: 16.73K Advanced Charting Volume:...

We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.Replimune ( REPL) shares fell early this month after the company disclosed in its latest 10Q filing that the FDA raised certain issues related to CERPASS, including those on study endpoints, for ...Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ... Rocket Pharmaceuticals, Inc. 22.82. +0.57. +2.54%. In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts. To skip our analysis of recent market ...Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.We would like to show you a description here but the site won’t allow us.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

8 Des 2022 ... ... Replimune's asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to ...

Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of ...Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies.Report of unscheduled material events or corporate event. 8-K. 0001104659-23-115027.pdf. 0001104659-23-115027.rtf. 0001104659-23-115027.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 07, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q.WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.The Replimune Group Inc. stock price fell by -1.34% on the last day (Wednesday, 22nd Nov 2023) from $10.43 to $10.29. During the last trading day the stock fluctuated 4.10% from a day low at $10.25 to a day high of $10.67. The price has fallen in 7 of the last 10 days and is down by -10.83% for this period.Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.

Founded Date Mar 2015. Founders Philip Sparke, Robert Coffin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Replimune Group Inc. Stock Symbol NASDAQ:REPL. Company Type For Profit. Contact Email [email protected]. Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the …Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...

Replimune Group, Inc. Stock price Equities REPL US76029N1063 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar …The Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.Replimune Group Stock Performance Shares of REPL stock opened at $11.71 on Monday. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.WOBURN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for its lead …Dec 1, 2023 · Earnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share. Replimune Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 8th, 2024 based off prior year's report dates. Today's Daily Dose brings you news about AnaptysBio's generalized pustular psoriasis trial results, Cyclerion discontinuing its Sickle Cell Disease drug program, FDA approving the first drug for Ebola, analyst's new price target of Replimune stock, and Vertex halting its phase II study of VX-814 in patients with alpha-1 antitrypsin deficiency.Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00. Replimune will have responsibility for operationalizing these clinical trials. ... the Company closed on an offering of common stock and pre-funded warrants raising approximately $259 million in ...

Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …

19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...

Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.The stock had previously closed at $10.40. Specifically, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $10.92, for a total transaction of $79,857.96.Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …Stock analysis for Replimune Group Inc (REPL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 30, 2023 · Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ... About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ...

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently …You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.2 days ago · What is the target price for Replimune Group (REPL) stock? A The latest price target for Replimune Group ( NASDAQ : REPL ) was reported by HC Wainwright & Co. on Monday, November 13, 2023 . 14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Instagram:https://instagram. how to buy sears stockhow to save money without a bank accountdoes nitro wood workcan i switch my health insurance Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ... Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 … nee stocksbest oil stocks 6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis. worth of 1979 susan b anthony dollar Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...